SCHEMBL4837030

SCHEMBL4837030

N#Cc1occ2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
ALDH1A1 P00352 9/20 0.38
KDM4E B2RXH2 7/20 0.38
GAA P10253 5/20 0.35
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
MAPT P10636 3/20 0.35
CACNA1B Q00975 1/20 0.35
APBA1 Q02410 1/20 0.35
CYP2A6 P11509 2/20 0.35
HSD17B10 Q99714 5/20 0.35
TSHR P16473 5/20 0.35
TDP1 Q9NUW8 1/20 0.35
HPGD P15428 4/20 0.34
CYP1A2 P05177 2/20 0.34
THRB P10828 1/20 0.34
ALOX15 P16050 4/20 0.34
ALOX12 P18054 3/20 0.34
CASP1 P29466 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL221413 0.78 ALDH1A1 (0.35) CA1CA2ALDH1A1KDM4EGAA
SCHEMBL9859801 0.70 ALDH1A1 (0.40) CA1CA2ALDH1A1GAAMAPT
SCHEMBL28217149 0.70 ALDH1A1 (0.39) ALDH1A1MEN1KMT2ACYP2A6HSD17B10
SCHEMBL22684751 0.70 CA1 (0.41) CA1CA2MEN1KMT2ATSHR
SCHEMBL11031530 0.69 KDM4E (0.35) CA1CA2ALDH1A1KDM4EGAA
SCHEMBL31429764 0.69 KDM4E (0.42) CA1CA2ALDH1A1KDM4EGAA
SCHEMBL4079696 0.65 CYP2A6 (0.42) ALDH1A1MAPTCYP2A6HSD17B10TSHR
SCHEMBL21179481 0.65 ALDH1A1 (0.39) ALDH1A1MEN1KMT2ACYP2A6HSD17B10
SCHEMBL4897405 0.65 ALDH1A1 (0.39) ALDH1A1MEN1KMT2ACYP2A6HSD17B10
SCHEMBL1097671 0.65 CYP2A6 (0.42) ALDH1A1KDM4EGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3620455-A1 NEW PREPARATION METHOD FOR ESCITALOPRAM PAMOATE Zhejiang Huahai Pharmaceutical Co., Ltd (CN) 2020-03-11 EP disclosed
CN-108976188-A A kind of preparation method that escitalopram embonate is new 上海奥博生物医药技术有限公司 2018-12-11 CN disclosed
CN-108976188-A A kind of preparation method that escitalopram embonate is new 上海奥博生物医药技术有限公司 2018-12-11 CN disclosed
US-7411077-B2 Process for the preparation of a cyano-isobenzofuran ADORKEN TECHNOLOGY SPA (IT) 2008-08-12 US disclosed
US-7411077-B2 Process for the preparation of a cyano-isobenzofuran ADORKEN TECHNOLOGY SPA (IT) 2008-08-12 US disclosed
US-20060293297-A1 Cyanofluoropyrrolidine derviative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2006-12-28 US disclosed
US-20060183925-A1 Process for the preparation of a cyano-isobenzofuran ADORKEM TECHNOLOGY SPA 2006-08-17 US disclosed
US-20060183925-A1 Process for the preparation of a cyano-isobenzofuran ADORKEM TECHNOLOGY SPA 2006-08-17 US disclosed
CN-1761658-A Process for the preparation of a cyano-isobenzofuran ADORKEM TECHNOLOGY SPA (IT) 2006-04-19 CN disclosed
CN-1761658-A Process for the preparation of a cyano-isobenzofuran ADORKEM TECHNOLOGY SPA (IT) 2006-04-19 CN disclosed
EP-1627870-A1 CYANOFLUOROPYRROLIDINE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2006-02-22 EP disclosed
EP-1601662-A1 PROCESS FOR THE PREPARATION OF A CYANO-ISOBENZOFURAN Adorkem Technology SpA (IT) 2005-12-07 EP disclosed
WO-2004080988-A1 PROCESS FOR THE PREPARATION OF A CYANO-ISOBENZOFURAN ADORKEM TECHNOLOGY SPA (IT) 2004-09-23 WO disclosed
CN-1129593-C Method for prepn. of citalopram LUNDBECK & CO AS H (DK) 2003-12-03 CN disclosed
CN-1356993-A Method for prepn. of citalopram LUNDBECK & CO AS H (DK) 2002-07-03 CN disclosed
US-4090027-A APPETITE SUPPRESSANTS HOFFMANN-LA ROCHE INC. (US) 1978-05-16 US disclosed
US-4077978-A APPETITE SUPPRESSANTS HOFFMANN-LA ROCHE INC. (US) 1978-03-07 US disclosed
US-3996374-A Isoindole derivatives as appetite suppressants HOFFMANN-LA ROCHE INC. (US) 1976-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293297-A1 Cyanofluoropyrrolidine derviative DPP4, DPP3, NPY4R CA1 1148/4885CA2 274/4885ALDH1A1 3197/4885
US-20060183925-A1 Process for the preparation of a cyano-isobenzofuran HTR1F, CYP4F12, CYP4F3 CA1 958/4885CA2 1032/4885ALDH1A1 574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.